1 Dollar, page-96

"PromarkerD as a Prognostic
 Predicts which patients are at risk of a significant & rapid decline in kidney function, better than any other known measure
 The preferred model of 3 biomarkers as a predictor of eGFR decline had an AUC of 0.83 with 89% sensitivity, 68% specificity
 People who have altered levels of protein from the biomarker panel are up to 7 times more likely to be in the eGFR decliner trajectory group"

Depending on the terms of course but if they nail a major
US Pharmaceutical partner to follow on from being awarded the patent
in the biggest market in the world then this should do a dollar easily.
Quite possibly much more.


From the September presentation.....

"Why PIQ?
Leveraged business model
Established income ~$1m per annum reduces burn
Analytics division underpins cash flow (revenue grew 27% in 2015)
Strong IP position
Patents pending in major jurisdictions for ground-breaking PromarkerD diagnostic
Proven technology platform
Proof of concept established with multiple applications for bespoke diagnostic tests, e.g. Alzheimer's
Established company in emerging sector
Key regional presence, but with global reach
Pending deal flow amidst fast-growing international activity
Commercialisation agreement in China & engaged with major US pharma 387 million, 10% uptake, $50 test, 5% royalty, $100 million per year

$100 million per year. I think people have started buying these up
on the potential upside of that statement alone. Current MC 24 million.

I personally like the long lead-in time this business has had.